Garuda Therapeutics is a biotechnology company focused on creating off-the-shelf hematopoietic stem cell therapies aimed at treating various severe and life-threatening conditions. The company specializes in addressing blood, bone marrow, immune, and metabolic diseases. By leveraging expertise in innovative research methods, including the use of zebrafish, mice, and human-induced pluripotent stem cells, Garuda analyzes novel genes and mechanisms vital for blood formation. This approach enables the development of mechanism-based therapies designed to improve patient outcomes.
Slingshot Biosciences aims to bring simple, elegant, and cost-effective solutions to common problems facing research and development programs. Our technology platform will make a significant bottom-line impact on the speed and cost of early-stage discovery, research and development programs.
CAMP4 Therapeutics Corporation, founded in 2015 and based in Cambridge, Massachusetts, is a bioinformatics company dedicated to advancing gene regulation technology. The company has developed a 4-D gene circuitry platform that codifies the activation of the 24,000 genes in the human body into a set of combinatorial rules based on signaling pathways. This innovative approach allows CAMP4 to control gene production by utilizing the existing mechanisms that regulate gene expression within cells. By focusing on the fundamental causes of diseases, CAMP4 aims to expedite the drug development process, significantly reducing both the time and risk associated with bringing new treatments to patients.
Molecule GmbH is a company that has developed a virtual accelerator platform aimed at facilitating the translation of scientific discoveries into new therapeutics. Founded in 2018 and headquartered in Neuhausen am Rheinfall, Switzerland, with an additional office in Berlin, Germany, Molecule connects scientists with the necessary funding for therapeutic development. This platform also links private investors directly with scientists, promoting the advancement of various treatments for patients. By streamlining the innovation process within the pharmaceutical industry, Molecule seeks to enhance the efficiency of bringing novel therapeutics to market.
Vizgen, Inc. is a biotechnology company focused on developing advanced spatially resolved transcriptomic profiling tools to enhance understanding of biological systems related to human health and disease. Its flagship technology, MERFISH, is a patented multiplexed single-molecule imaging method that allows for the simultaneous measurement of RNA species' copy number and spatial distribution within individual cells. This innovative approach facilitates single-cell gene expression profiling in intact tissue slices, providing valuable insights into various diseases and biological processes. The applications of Vizgen's technology span several fields, including oncology, immunology, neuroscience, infectious diseases, developmental biology, and regenerative medicine. Founded in 2019 and headquartered in Cambridge, Massachusetts, Vizgen aims to support tissue-scale research and development, contributing to the discovery and mapping of diverse cell types and states across multiple tissues and organisms.
Transition Bio, Inc. is a biotechnology company that specializes in the discovery, analysis, and modulation of biological condensates. Established in 2020 and headquartered in Cambridge, Massachusetts, with an additional office in Cambridge, United Kingdom, the company has developed a unique platform known as Condensomics. This hypothesis-free drug discovery and diagnostics technology allows for expansive opportunities in drug development by leveraging the intricate properties of biological condensates. Transition Bio's innovative approach aims to advance the understanding and application of these biological structures in the field of medicine.
OMass Technologies Ltd engages in drug discovery by applying mass spectrometry to the characterization of intact protein assemblies. The company offers biotherapeutics, membrane proteins, drug binding, and purifications guiding services. In addition, OMass Technologies Ltd offers structural mass spectrometry (MS) platforms, often referred to as native mass spectrometry, for characterizing complex protein assemblies. The company assists biotechnology and pharmaceutical companies in tackling drug targets and biotherapeutics. OMass Technologies Ltd was founded in 2016 and is based in Begbroke, United Kingdom.
Ansa Biotechnologies, Inc. is a biotechnology company based in Berkeley, California, focused on developing innovative DNA synthesis technology utilizing enzymes. Established in 2018, the company aims to improve upon traditional chemical methods of DNA synthesis that have remained largely unchanged for decades. Ansa's enzymatic approach offers significant advantages, including increased speed, accuracy, and cleanliness in the production of DNA fragments such as oligonucleotides. This technology enhances the capabilities of biological research, therapeutics, diagnostics, and biomanufacturing by enabling the synthesis of gene-length oligonucleotides. Through its advancements, Ansa Biotechnologies seeks to facilitate innovation in the fields of biological research and engineering, ultimately providing valuable services to medical researchers and contributing to the broader biotechnology landscape.
Eleanor Health is a provider of rehabilitation services focused on mental health and substance misuse. Founded in 2019, the company offers comprehensive, whole-person care through a network of outpatient clinics, virtual platforms, and community settings, including patients' homes. Eleanor Health emphasizes long-term recovery outcomes and employs a value-based care model. In addition to rehabilitation, the company connects individuals with essential resources such as housing, employment, and peer support, ensuring a holistic approach to recovery. Headquartered in Waltham, Massachusetts, Eleanor Health aims to improve the lives of those facing addiction and mental health challenges.
Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Their proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer.
DNAnexus, Inc. specializes in cloud-based genome informatics and data management tools tailored for enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company provides a platform that facilitates the analysis of raw sequencing data, integrates genomic data with clinical information, and enhances collaboration among researchers. Key offerings include the MOSAIC Microbiome platform for microbiome research, DNAnexus Apollo for clinico-genomic data exploration, DNAnexus Titan for data analysis, and DNAnexus Portals, which create secure online workspaces for collaborative projects. Additionally, the Clinico-Genomic Data Solution aims to enhance disease-specific datasets through partnerships with healthcare providers, improving screening and treatment pathways for complex diseases. DNAnexus serves a diverse clientele, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.
Sherlock Biosciences, Inc., a biotechnology company, develops molecular diagnostics solutions. It offers SHERLOCK, a CRISPR-based method to detect and quantify specific genetic sequences, and INSPECTR, a synthetic biology-based molecular diagnostics platform. The company offers its products in the areas of precision oncology, infection identification, food safety, at-home tests, and disease detection. The company was incorporated in 2018 and is based in Cambridge, Massachusetts.
Scipher Medicine is a biotechnology company based in Waltham, Massachusetts, that focuses on developing a molecular technology platform to predict patient responses to drug therapies, particularly in cardiovascular and autoimmune diseases. The company offers several diagnostic tests, including PrismDx, which identifies patients who may not respond to specific medications, PrismRA for patients with rheumatoid arthritis, and PrismUC for those with ulcerative colitis. These tests enable healthcare providers to prescribe more suitable alternative therapies for patients who are unlikely to benefit from traditional treatments. Scipher Medicine emphasizes the importance of providing scientifically backed data to improve patient outcomes and enhance treatment decisions. The company has also established a strategic partnership with Ambry Genetics Corporation to further advance its capabilities. Founded in 2014, Scipher Medicine was previously known as DZZOM Delaware Corporation before changing its name in 2015.
Story Health Corporation, founded in 2020 and based in Saratoga, California, develops advanced virtual clinical care software tools aimed at assisting healthcare specialists, particularly neurologists and primary care physicians. The company's platform utilizes data from high-frequency sources to enhance clinical decision-making and improve patient therapy management. By integrating virtual protocols and adaptive machine learning, Story Health empowers clinicians to bridge the gap between clinical evidence and patient realities. Its focus on patient-centered design facilitates a deeper understanding of the physiological effects of diseases and therapies, ultimately aiming to optimize patient care and outcomes in specialty healthcare settings.
Walking Fish Therapeutics is developing a platform to harness B cells’ capability to activate the immune system in the treatment of cancer, and to serve as in vivo protein factories that produce replacement proteins for deficiency diseases, regenerative proteins, and engineered antibodies.
1859 is a biotechnology company focusing on the discovery and development of next-generation therapeutics.
The company was founded in 2019 and is headquartered in San Diego, California.
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Berkeley, California, specializing in the development of cell therapies for serious autoimmune diseases. Founded in 2018, Kyverna employs advanced T cell engineering and synthetic biology technologies to target and eliminate autoreactive immune cells, addressing the root causes of inflammatory diseases. The company is advancing its therapeutic platform with product candidates such as KYV-101, an autologous CD19 CAR T-cell therapy, and KYV-201, an allogeneic version utilizing the same chimeric antigen receptor. Through these innovative approaches, Kyverna aims to provide effective treatments and potential cures for patients suffering from autoimmune conditions.
64x Bio is a biotechnology company based in San Francisco, California, founded in 2017 by Alexis Rovner, George Church, Jeffrey Way, and Pamela Silver. The company specializes in designing microorganisms with enhanced properties to facilitate advanced applications in biomanufacturing, bioremediation, and health. By creating cells tailored for specific purposes, 64x Bio aims to enable innovative solutions that were previously unattainable in these fields.
Ori Biotech is a developer of a manufacturing platform used to help patients get access to lifesaving treatments. Ori has developed a proprietary, flexible manufacturing platform that closes, automates, and standardizes manufacturing allowing therapeutics developers to further develop and bring their products from pre-clinical process development to commercial-scale manufacturing. The company aims to speed up the innovation of cell and gene therapies through the manufacturing platform it is bringing to market.
Scitara offers a unique cloud-based connectivity platform that transforms integration between instruments and lab informatics applications. The Scitara Cloud-based technology provides a standardized platform for communication and automated workflows lab wide. This dramatically simplifies the overall integration framework and makes automation possible where it was not possible before. The company was founded in 2019 and based in Marlborough, Massachusetts.
Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time.
SimBioSys, Inc. is developing a Computational Microscope that integrates state-of-the-art simulation techniques with a diverse set of experimental datasets to provide new insight into the behavior of cancers. The technology allows researchers to peer into the cancer microenvironment to identify the behavior of tumors: the cell phenotypes, how they interact with surrounding tissues, and how they prime their neighbors for invasion, all from the comfort of their computer desk.
Culture Biosciences, founded in 2016 and headquartered in San Francisco, California, specializes in developing automated bioreactors and tools for fermentation. The company provides a digital bio-manufacturing platform that allows biotech companies to optimize their manufacturing processes, enabling them to bring products to market more efficiently. By utilizing robotic sample handling and cloud-based data monitoring and analysis, Culture Biosciences helps scientists run, monitor, and analyze bioreactors more quickly than traditional methods. This innovative approach supports the biotechnology sector in enhancing productivity and streamlining workflows.
Kytopen Corp. is a biotechnology company based in Cambridge, Massachusetts, focused on advancing cell therapy through its innovative Flowfect technology. Established in 2017, Kytopen specializes in non-viral delivery systems for molecules into challenging immune cells that are typically hard to transfect. The company utilizes a combination of microfluidics and automation to streamline the delivery process, making it faster, more efficient, and cost-effective. By employing a unique platform that integrates continuous fluid flow with electric fields, Kytopen enables researchers to produce high-quality engineered cells in a matter of minutes while preserving their health and functionality. This approach supports the discovery of novel biological insights and the development of affordable cell and gene therapies.
Garuda Therapeutics is a biotechnology company focused on creating off-the-shelf hematopoietic stem cell therapies aimed at treating various severe and life-threatening conditions. The company specializes in addressing blood, bone marrow, immune, and metabolic diseases. By leveraging expertise in innovative research methods, including the use of zebrafish, mice, and human-induced pluripotent stem cells, Garuda analyzes novel genes and mechanisms vital for blood formation. This approach enables the development of mechanism-based therapies designed to improve patient outcomes.
Elephas is a live tumor imaging diagnostics company focused on enhancing cancer treatment through personalized therapy determination. The company leverages advancements in cancer biology, multimodal microscopy, engineering, and artificial intelligence to analyze human live tumor fragments. This innovative platform aims to improve clinical decision-making for oncologists, enabling them to tailor treatments to individual patients. Additionally, Elephas seeks to accelerate drug development processes, addressing the urgent need for effective cancer therapies in a rapidly evolving healthcare landscape.
Emulate, Inc. specializes in organs-on-chips technology designed to mimic human biology, enabling a better understanding of how diseases, medications, chemicals, and food impact human health. The company offers organ-chips that replicate the functions and disease states of various human organs, including the lung, intestine, liver, and skin. In addition to its organ-chips, Emulate provides software applications for drug development and research workflows, catering to a diverse clientele that includes biotechnology and pharmaceutical companies, consumer health and cosmetics industries, agricultural firms, and academic researchers. Founded in 2013 and based in Boston, Massachusetts, Emulate aims to set a new standard for accurately predicting human responses across multiple fields, including drug development and personalized medicine. The company was previously known as Emulate Living MicroDevices, Inc. before rebranding in 2014.
DiCE Therapeutics, founded in 2013 and based in Menlo Park, California, specializes in developing a platform for the discovery of novel small molecules aimed at targets that have previously been difficult to address in the pharmaceutical sector. The company utilizes innovative technology that extends directed evolution, allowing for the direct translation of DNA-encoded information into organic compounds, thereby streamlining the traditionally labor-intensive processes of medicinal chemistry. This platform not only serves the pharmaceutical industry but also has applications in agriculture and materials sciences. The founding team includes notable figures such as Stanford Professor Pehr Harbury, who developed the core technology, and other experienced professionals from various sectors, contributing to the company's mission of transforming drug discovery and development.
Sound Agriculture uses molecular discovery to create climate-resilient crops, enhancing harvest yields for growers. They also use an innovative life science approach to sustainably increase farming productivity.
The company was founded in 2013 and headquartered in Emeryville, California.
Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.
Slingshot Biosciences aims to bring simple, elegant, and cost-effective solutions to common problems facing research and development programs. Our technology platform will make a significant bottom-line impact on the speed and cost of early-stage discovery, research and development programs.
CAMP4 Therapeutics Corporation, founded in 2015 and based in Cambridge, Massachusetts, is a bioinformatics company dedicated to advancing gene regulation technology. The company has developed a 4-D gene circuitry platform that codifies the activation of the 24,000 genes in the human body into a set of combinatorial rules based on signaling pathways. This innovative approach allows CAMP4 to control gene production by utilizing the existing mechanisms that regulate gene expression within cells. By focusing on the fundamental causes of diseases, CAMP4 aims to expedite the drug development process, significantly reducing both the time and risk associated with bringing new treatments to patients.
Hawthorne Effect's mission is to make clinical trials accessible to everyone, everywhere. The company's proactive Visit Management System honors the relationship between sponsors and their investigators and promotes the use of shared technology to ensure protocol compliance and eliminate missing data. By enabling research teams to not only track all of their patients and thousands of data points but deploy specially trained healthcare providers (“HEROs”) to conduct visits anywhere, anytime, Hawthorne Effect ensures that no patients are “lost to follow-up.
Clinical protocols are scientific decisions wrapped in administrative burden. The Faro system handles the tedious work better left for a computer, freeing clinical researchers to focus on the important decisions that drive clinical value.
Torus Biosystems offers an apparatus for DNA testing for scientific and medical research purposes in the fields of consumer products, food for human beings or animals, hygienic and beauty care for human beings or animals, agriculture, horticulture, and forestry.
Monoclonal antibodies make up an effective and rapidly growing class of drugs. They are also critical research tools and essential for the development of many new diagnostics. Isolere Bio was co-founded with the vision of simplifying and streamlining the purification of biotherapeutics to improve global access to these important drugs.
Outcomes4Me is a developer of a free mobile app and platform to navigate cancer treatment and care. It provides patients and their families with new ways to engage with healthcare systems globally. It aims to help them seamlessly discover and access personalized treatment options and outcomes information. It believes that patients can and should be empowered with their own care.
It was founded in 2017 and is headquartered in Cambridge, Massachusetts.
Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and will eventually be valuable for clinical diagnostic use.
It was founded in 2015 and headquartered in Cambridge, Massachusetts.
Current Health Limited manufactures wearable healthcare devices to measure patient’s vitals and to alert in case of emergency. The product identifies unwell patients to make early decisions. The product can be used to measure oxygen saturation, respiration rate, pulse rate, temperature, motion & activity, and posture. Current Health Limited was formerly known as Snap40 Limited and changed its name to Current Health Limited in December 2018. Current Health Limited was founded in 2014 and is based in Edinburgh, United Kingdom.
VieCure built an engine to turn data into knowledge and take the world’s best thinking to clinicians and patients in real time. They codify the world’s premier cancer information in an engine that considers each patient’s unique needs and creates the most personalized comprehensive care plan. By accessing our evidence-based knowledge, oncologists can create actionable cancer patient-specific personalized treatment plans that comply with nationally-accepted standards and the latest genomic-based guidelines.
Vizgen, Inc. is a biotechnology company focused on developing advanced spatially resolved transcriptomic profiling tools to enhance understanding of biological systems related to human health and disease. Its flagship technology, MERFISH, is a patented multiplexed single-molecule imaging method that allows for the simultaneous measurement of RNA species' copy number and spatial distribution within individual cells. This innovative approach facilitates single-cell gene expression profiling in intact tissue slices, providing valuable insights into various diseases and biological processes. The applications of Vizgen's technology span several fields, including oncology, immunology, neuroscience, infectious diseases, developmental biology, and regenerative medicine. Founded in 2019 and headquartered in Cambridge, Massachusetts, Vizgen aims to support tissue-scale research and development, contributing to the discovery and mapping of diverse cell types and states across multiple tissues and organisms.
Scipher Medicine is a biotechnology company based in Waltham, Massachusetts, that focuses on developing a molecular technology platform to predict patient responses to drug therapies, particularly in cardiovascular and autoimmune diseases. The company offers several diagnostic tests, including PrismDx, which identifies patients who may not respond to specific medications, PrismRA for patients with rheumatoid arthritis, and PrismUC for those with ulcerative colitis. These tests enable healthcare providers to prescribe more suitable alternative therapies for patients who are unlikely to benefit from traditional treatments. Scipher Medicine emphasizes the importance of providing scientifically backed data to improve patient outcomes and enhance treatment decisions. The company has also established a strategic partnership with Ambry Genetics Corporation to further advance its capabilities. Founded in 2014, Scipher Medicine was previously known as DZZOM Delaware Corporation before changing its name in 2015.
Inflammatix, Inc. is a molecular diagnostics company based in Burlingame, California, established in 2016. The company specializes in developing rapid tests that analyze the immune system to address significant clinical and public health challenges, particularly in the diagnosis of acute bacterial and viral infections, as well as sepsis. Utilizing patent-pending biomarkers exclusively licensed from Stanford University, Inflammatix aims to create clinically actionable results through proprietary machine-learning algorithms. In addition to its focus on acute infections and sepsis, the company is expanding its diagnostics pipeline to include tests for tropical infections, autoimmune diseases, transplant rejection, and other medical conditions, ultimately assisting healthcare providers in making informed diagnostic decisions.
StrideBio, Inc. creates and develops adeno-associated viral (AAV) vector technologies and therapeutics that enables gene addition, gene silencing, and gene editing modalities for rare diseases. The company develops a proprietary platform by combining structural information with accelerated evolution to create novel AAV capsids that can evade neutralizing antibodies. The company was founded in 2015 and is based in Durham, North Carolina.
Vestaron Corporation is a biotechnology company that specializes in developing, manufacturing, and selling peptide-based biologic crop protection products. Founded in 2005 and headquartered in Durham, North Carolina, with a research and development center in Kalamazoo, Michigan, Vestaron offers a range of bioinsecticides including Spear-T for thrips in vegetables and ornamentals, Spear-Lep for various fruits and vegetables, and Leprotec for field use. The company's products are designed to enhance the safety, efficacy, and sustainability of agricultural practices while being safe for humans, birds, fish, and pollinators. By utilizing peptides derived from spiders, Vestaron aims to provide innovative solutions for agriculture, animal health, and commercial pest control applications.
Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basis of human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States.
Scitara offers a unique cloud-based connectivity platform that transforms integration between instruments and lab informatics applications. The Scitara Cloud-based technology provides a standardized platform for communication and automated workflows lab wide. This dramatically simplifies the overall integration framework and makes automation possible where it was not possible before. The company was founded in 2019 and based in Marlborough, Massachusetts.
Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, that specializes in early cancer detection through non-invasive blood tests. Founded in 2018, the company utilizes advanced artificial intelligence and genome sequencing technologies to identify unique patterns of DNA fragmentation in patients' blood, enabling the detection of cancer at its most treatable stage. By focusing on precision diagnostics, Delfi Diagnostics aims to improve patient outcomes and contribute to the evolving landscape of cancer care.
DiCE Therapeutics, founded in 2013 and based in Menlo Park, California, specializes in developing a platform for the discovery of novel small molecules aimed at targets that have previously been difficult to address in the pharmaceutical sector. The company utilizes innovative technology that extends directed evolution, allowing for the direct translation of DNA-encoded information into organic compounds, thereby streamlining the traditionally labor-intensive processes of medicinal chemistry. This platform not only serves the pharmaceutical industry but also has applications in agriculture and materials sciences. The founding team includes notable figures such as Stanford Professor Pehr Harbury, who developed the core technology, and other experienced professionals from various sectors, contributing to the company's mission of transforming drug discovery and development.
Encodia, Inc. engages in proteomics research and creates scalable and parallelized approaches to protein analysis. The company was founded in 2015 and is based in San Diego, California.
Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases. Centyrins are small, non-antibody protein scaffolds that can be expressed as multi-specifics with novel therapeutic mechanisms of action. Centyrins are also ideal for the targeted delivery of complex drug payloads, including nucleic acids.
Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States.
NanoView Biosciences, founded in 2015 and based in Boston, Massachusetts, specializes in the development of innovative technologies for the characterization of extracellular vesicles, particularly exosomes. The company's proprietary ExoView technology uses an affinity microarray platform to enable specific binding and detection of these vesicles, facilitating high-throughput and cost-effective analysis. NanoView offers a range of products, including ExoView R100 and ExoView Tetraspanin, along with custom assays and sample services. The company's solutions aim to enhance research and the delivery of precision medicine by providing insights into the biological roles of exosomes and their potential as biomarkers for disease diagnosis, treatment, and monitoring.
Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.
General Automation Lab Technologies, Inc. discovers, develops, and commercializes gut microbe systems for microbial research and product development communities. It offers GALT Prospector, a high-throughput isolation and cultivation array system that enables scientists to access various microbes; and isolate rare/unique species to understand their functions. Its microbe systems are used in cultivation, screening, and natural product discovery applications. General Automation Lab Technologies, Inc. was founded in 2014 and is based in San Carlos, California.
Refeyn specializes in label-free single molecule imaging and mass measurement, offering advanced microscopy solutions for detecting and quantifying molecules. Their technology enables users to perform precise imaging, localization, and accurate mass determination of individual biomolecules in solution. This innovative approach serves various sectors, particularly pharmaceutical, biomedical, and research industries. Founded in 2018 and headquartered in Oxford, United Kingdom, Refeyn aims to enhance research capabilities by providing tools that facilitate a deeper understanding of molecular interactions and properties.
Ori Biotech is a developer of a manufacturing platform used to help patients get access to lifesaving treatments. Ori has developed a proprietary, flexible manufacturing platform that closes, automates, and standardizes manufacturing allowing therapeutics developers to further develop and bring their products from pre-clinical process development to commercial-scale manufacturing. The company aims to speed up the innovation of cell and gene therapies through the manufacturing platform it is bringing to market.
Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.
Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Their proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer.
DNAnexus, Inc. specializes in cloud-based genome informatics and data management tools tailored for enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company provides a platform that facilitates the analysis of raw sequencing data, integrates genomic data with clinical information, and enhances collaboration among researchers. Key offerings include the MOSAIC Microbiome platform for microbiome research, DNAnexus Apollo for clinico-genomic data exploration, DNAnexus Titan for data analysis, and DNAnexus Portals, which create secure online workspaces for collaborative projects. Additionally, the Clinico-Genomic Data Solution aims to enhance disease-specific datasets through partnerships with healthcare providers, improving screening and treatment pathways for complex diseases. DNAnexus serves a diverse clientele, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.
Emulate, Inc. specializes in organs-on-chips technology designed to mimic human biology, enabling a better understanding of how diseases, medications, chemicals, and food impact human health. The company offers organ-chips that replicate the functions and disease states of various human organs, including the lung, intestine, liver, and skin. In addition to its organ-chips, Emulate provides software applications for drug development and research workflows, catering to a diverse clientele that includes biotechnology and pharmaceutical companies, consumer health and cosmetics industries, agricultural firms, and academic researchers. Founded in 2013 and based in Boston, Massachusetts, Emulate aims to set a new standard for accurately predicting human responses across multiple fields, including drug development and personalized medicine. The company was previously known as Emulate Living MicroDevices, Inc. before rebranding in 2014.
SpeeDx is a company that specializes in molecular diagnostic solutions aimed at enhancing patient management through comprehensive information. Utilizing innovative real-time polymerase chain reaction (qPCR) technology, SpeeDx offers a leading portfolio of multiplex diagnostic tests. These tests are particularly focused on sexually transmitted infections (STIs), antibiotic resistance markers, and respiratory diseases. By employing advanced multiplex detection and priming strategies, SpeeDx enables healthcare providers to effectively diagnose infectious diseases and assess antibiotic resistance, ultimately improving clinical outcomes.
Intabio, Inc. specializes in developing analytical solutions designed to enhance the efficiency of biopharmaceutical development and manufacturing processes. Founded in 2015 and based in Newark, California, the company offers the Blaze system, which includes a bench-top instrument, a microfluidic chip, and a reagent kit. This system facilitates the separation, quantitation, and identification of molecular mass for intact biotherapeutic proteins, allowing for real-time characterization of protein isoforms. Intabio's technology addresses the challenges faced in the development and manufacturing of biologics, which often involve unintended structural modifications that can impact drug efficacy and safety. By providing rapid and direct analysis, Intabio's platform aims to reduce the cumbersome testing processes currently used in the industry, enabling better monitoring and product quality assessment while minimizing potential delays and costly missteps in drug development.
Vizgen, Inc. is a biotechnology company focused on developing advanced spatially resolved transcriptomic profiling tools to enhance understanding of biological systems related to human health and disease. Its flagship technology, MERFISH, is a patented multiplexed single-molecule imaging method that allows for the simultaneous measurement of RNA species' copy number and spatial distribution within individual cells. This innovative approach facilitates single-cell gene expression profiling in intact tissue slices, providing valuable insights into various diseases and biological processes. The applications of Vizgen's technology span several fields, including oncology, immunology, neuroscience, infectious diseases, developmental biology, and regenerative medicine. Founded in 2019 and headquartered in Cambridge, Massachusetts, Vizgen aims to support tissue-scale research and development, contributing to the discovery and mapping of diverse cell types and states across multiple tissues and organisms.
Inflammatix, Inc. is a molecular diagnostics company based in Burlingame, California, established in 2016. The company specializes in developing rapid tests that analyze the immune system to address significant clinical and public health challenges, particularly in the diagnosis of acute bacterial and viral infections, as well as sepsis. Utilizing patent-pending biomarkers exclusively licensed from Stanford University, Inflammatix aims to create clinically actionable results through proprietary machine-learning algorithms. In addition to its focus on acute infections and sepsis, the company is expanding its diagnostics pipeline to include tests for tropical infections, autoimmune diseases, transplant rejection, and other medical conditions, ultimately assisting healthcare providers in making informed diagnostic decisions.
IsoPlexis Corp is a life sciences company based in Branford, Connecticut, that specializes in developing a diagnostic platform designed to measure cellular immune responses in patients. Founded in 2013, the company's technology focuses on single-cell detection, allowing for the identification of diverse immune responses at the individual cell level. This platform plays a crucial role in assessing the safety and efficacy of therapeutics, as well as monitoring disease progression. By providing detailed insights into immune responses, IsoPlexis aims to enhance therapeutic development and inform clinical decision-making for healthcare professionals.
IsoPlexis Corp is a life sciences company based in Branford, Connecticut, that specializes in developing a diagnostic platform designed to measure cellular immune responses in patients. Founded in 2013, the company's technology focuses on single-cell detection, allowing for the identification of diverse immune responses at the individual cell level. This platform plays a crucial role in assessing the safety and efficacy of therapeutics, as well as monitoring disease progression. By providing detailed insights into immune responses, IsoPlexis aims to enhance therapeutic development and inform clinical decision-making for healthcare professionals.
SGI-DNA provides a variety of synthetic genomic solutions to advance your research. Our comprehensive suite of genomic services will allow you to discover, design, and build the sequences you need. We are committed to reducing barriers associated with DNA synthesis and sequence analysis by leveraging the technology developed at the J. Craig Venter Institute and Synthetic Genomics, Inc. SGI-DNA, a wholly owned subsidiary of Synthetic Genomics, Inc (SGI), was founded in 2013 and is headquartered in La Jolla, CA. Building on the scientific advancements and breakthroughs from leading scientists such as J. Craig Venter, Ham Smith, Clyde Hutchison, Dan Gibson and their teams, SGI-DNA utilizes unique and proprietary DNA technologies to produce complex synthetic genes and reagents. SGI-DNA also offers a comprehensive suite of genomic services, including whole genome sequencing, library design, and other bioinformatics services. SGI-DNA is responsible for all commercial aspects of SGI’s synthetic DNA business and focuses on strategic business relationships with both academic and commercial researchers.
ChromaCode, Inc. is a molecular diagnostics company based in Carlsbad, California, specializing in testing solutions for infectious diseases, cancer, and non-invasive prenatal testing (NIPT). Founded in 2012, the company leverages patented mathematical methods and algorithmic enhancements derived from Caltech intellectual property to improve signal processing in life science instrumentation. This technology enables ChromaCode to significantly enhance the multiplexing capabilities of quantitative polymerase chain reaction (qPCR) instruments, allowing for more efficient and cost-effective biochemical assays. Among its offerings is the HDPCR Tick-Borne Pathogen Panel, which detects multiple common tick-borne pathogens in a single test. ChromaCode’s expertise is bolstered by a team with backgrounds in leading organizations such as Illumina, Google[x], and Luminex.
Intabio, Inc. specializes in developing analytical solutions designed to enhance the efficiency of biopharmaceutical development and manufacturing processes. Founded in 2015 and based in Newark, California, the company offers the Blaze system, which includes a bench-top instrument, a microfluidic chip, and a reagent kit. This system facilitates the separation, quantitation, and identification of molecular mass for intact biotherapeutic proteins, allowing for real-time characterization of protein isoforms. Intabio's technology addresses the challenges faced in the development and manufacturing of biologics, which often involve unintended structural modifications that can impact drug efficacy and safety. By providing rapid and direct analysis, Intabio's platform aims to reduce the cumbersome testing processes currently used in the industry, enabling better monitoring and product quality assessment while minimizing potential delays and costly missteps in drug development.
General Automation Lab Technologies, Inc. discovers, develops, and commercializes gut microbe systems for microbial research and product development communities. It offers GALT Prospector, a high-throughput isolation and cultivation array system that enables scientists to access various microbes; and isolate rare/unique species to understand their functions. Its microbe systems are used in cultivation, screening, and natural product discovery applications. General Automation Lab Technologies, Inc. was founded in 2014 and is based in San Carlos, California.
SGI-DNA provides a variety of synthetic genomic solutions to advance your research. Our comprehensive suite of genomic services will allow you to discover, design, and build the sequences you need. We are committed to reducing barriers associated with DNA synthesis and sequence analysis by leveraging the technology developed at the J. Craig Venter Institute and Synthetic Genomics, Inc. SGI-DNA, a wholly owned subsidiary of Synthetic Genomics, Inc (SGI), was founded in 2013 and is headquartered in La Jolla, CA. Building on the scientific advancements and breakthroughs from leading scientists such as J. Craig Venter, Ham Smith, Clyde Hutchison, Dan Gibson and their teams, SGI-DNA utilizes unique and proprietary DNA technologies to produce complex synthetic genes and reagents. SGI-DNA also offers a comprehensive suite of genomic services, including whole genome sequencing, library design, and other bioinformatics services. SGI-DNA is responsible for all commercial aspects of SGI’s synthetic DNA business and focuses on strategic business relationships with both academic and commercial researchers.
SeLux Diagnostics, Inc. is focused on advancing antibiotic susceptibility testing and infectious disease diagnostics through its innovative phenotyping platform. Founded in 2014 and located in Charlestown, Massachusetts, the company employs a unique synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing. This platform significantly improves the accuracy and timeliness of diagnosing infections, enabling healthcare providers to prescribe targeted and personalized antibiotic therapies. By facilitating informed treatment decisions, SeLux Diagnostics aims to enhance patient care, save lives, and improve overall health outcomes in hospital settings.
SpeeDx is a company that specializes in molecular diagnostic solutions aimed at enhancing patient management through comprehensive information. Utilizing innovative real-time polymerase chain reaction (qPCR) technology, SpeeDx offers a leading portfolio of multiplex diagnostic tests. These tests are particularly focused on sexually transmitted infections (STIs), antibiotic resistance markers, and respiratory diseases. By employing advanced multiplex detection and priming strategies, SpeeDx enables healthcare providers to effectively diagnose infectious diseases and assess antibiotic resistance, ultimately improving clinical outcomes.
SpeeDx is a company that specializes in molecular diagnostic solutions aimed at enhancing patient management through comprehensive information. Utilizing innovative real-time polymerase chain reaction (qPCR) technology, SpeeDx offers a leading portfolio of multiplex diagnostic tests. These tests are particularly focused on sexually transmitted infections (STIs), antibiotic resistance markers, and respiratory diseases. By employing advanced multiplex detection and priming strategies, SpeeDx enables healthcare providers to effectively diagnose infectious diseases and assess antibiotic resistance, ultimately improving clinical outcomes.
Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and will eventually be valuable for clinical diagnostic use.
It was founded in 2015 and headquartered in Cambridge, Massachusetts.
IsoPlexis Corp is a life sciences company based in Branford, Connecticut, that specializes in developing a diagnostic platform designed to measure cellular immune responses in patients. Founded in 2013, the company's technology focuses on single-cell detection, allowing for the identification of diverse immune responses at the individual cell level. This platform plays a crucial role in assessing the safety and efficacy of therapeutics, as well as monitoring disease progression. By providing detailed insights into immune responses, IsoPlexis aims to enhance therapeutic development and inform clinical decision-making for healthcare professionals.
Scipher Medicine is a biotechnology company based in Waltham, Massachusetts, that focuses on developing a molecular technology platform to predict patient responses to drug therapies, particularly in cardiovascular and autoimmune diseases. The company offers several diagnostic tests, including PrismDx, which identifies patients who may not respond to specific medications, PrismRA for patients with rheumatoid arthritis, and PrismUC for those with ulcerative colitis. These tests enable healthcare providers to prescribe more suitable alternative therapies for patients who are unlikely to benefit from traditional treatments. Scipher Medicine emphasizes the importance of providing scientifically backed data to improve patient outcomes and enhance treatment decisions. The company has also established a strategic partnership with Ambry Genetics Corporation to further advance its capabilities. Founded in 2014, Scipher Medicine was previously known as DZZOM Delaware Corporation before changing its name in 2015.
908 Devices Inc. develops and sells measurement devices for chemical and biochemical analysis globally, including the United States, China, Japan, and Europe. Founded in 2012 and headquartered in Boston, Massachusetts, the company utilizes mass spectrometry technology to create handheld and desktop devices suitable for various applications in life sciences research, bioprocessing, industrial biotech, and forensics. Notable products include the MX908, a portable, battery-operated mass spectrometry device designed for the rapid analysis of unknown materials in various states; the Rebel, a desktop analyzer that provides real-time data on bioprocess environments; and the ZipChip, a high-resolution separation platform that enhances mass spectrometry sample analysis. 908 Devices aims to make the capabilities of mass spectrometry accessible beyond traditional laboratories, offering rugged and reliable tools for immediate field use.
Sherlock Biosciences, Inc., a biotechnology company, develops molecular diagnostics solutions. It offers SHERLOCK, a CRISPR-based method to detect and quantify specific genetic sequences, and INSPECTR, a synthetic biology-based molecular diagnostics platform. The company offers its products in the areas of precision oncology, infection identification, food safety, at-home tests, and disease detection. The company was incorporated in 2018 and is based in Cambridge, Massachusetts.
Deep Lens is a provider of a digital pathology workflow platform intended to allow pathology groups to collaborate on groundbreaking cancer research. The company's platform includes AI-powered image detection and workflow support, collaboration, cloud storage, and built-in APIs for the ingestion of third-party AI models and integration to EMR, LIMS, and other systems, helping patients, pathologists, and physicians work together to accelerate and optimize treatment.
Founded in 2017, Deep Lens is headquartered in Columbus, Ohio.
Candel develops cancer immunotherapies designed to improve the lives of cancer patients and their families. The company's immunotherapies focus on preventing the recurrence and progression of cancer with low toxicity level which is well suited for the treatment of less aggressive or slower growing cancers such as newly diagnosed prostate cancer, enabling physicians to ensure improved outcomes for their patients and help them recover faster.
Teckro, Inc. offers a solution that transforms clinical trials making all relevant information instantly accessible to every active member of the study. The company facilitates connections between investigators and the expertise they need; and helps study teams, sites, and patients to connect. Its solution instantly captures and shares team’s knowledge to dramatically reduce the burden on CRAs, medical monitors, data management, and study personnel. The company serves pharmaceutical companies and clinical researchers across the world. Teckro, Inc. was incorporated in 2015 and is based in Limerick, Ireland.
SeLux Diagnostics, Inc. is focused on advancing antibiotic susceptibility testing and infectious disease diagnostics through its innovative phenotyping platform. Founded in 2014 and located in Charlestown, Massachusetts, the company employs a unique synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing. This platform significantly improves the accuracy and timeliness of diagnosing infections, enabling healthcare providers to prescribe targeted and personalized antibiotic therapies. By facilitating informed treatment decisions, SeLux Diagnostics aims to enhance patient care, save lives, and improve overall health outcomes in hospital settings.
Intabio, Inc. specializes in developing analytical solutions designed to enhance the efficiency of biopharmaceutical development and manufacturing processes. Founded in 2015 and based in Newark, California, the company offers the Blaze system, which includes a bench-top instrument, a microfluidic chip, and a reagent kit. This system facilitates the separation, quantitation, and identification of molecular mass for intact biotherapeutic proteins, allowing for real-time characterization of protein isoforms. Intabio's technology addresses the challenges faced in the development and manufacturing of biologics, which often involve unintended structural modifications that can impact drug efficacy and safety. By providing rapid and direct analysis, Intabio's platform aims to reduce the cumbersome testing processes currently used in the industry, enabling better monitoring and product quality assessment while minimizing potential delays and costly missteps in drug development.
Inflammatix, Inc. is a molecular diagnostics company based in Burlingame, California, established in 2016. The company specializes in developing rapid tests that analyze the immune system to address significant clinical and public health challenges, particularly in the diagnosis of acute bacterial and viral infections, as well as sepsis. Utilizing patent-pending biomarkers exclusively licensed from Stanford University, Inflammatix aims to create clinically actionable results through proprietary machine-learning algorithms. In addition to its focus on acute infections and sepsis, the company is expanding its diagnostics pipeline to include tests for tropical infections, autoimmune diseases, transplant rejection, and other medical conditions, ultimately assisting healthcare providers in making informed diagnostic decisions.
NanoView Biosciences, founded in 2015 and based in Boston, Massachusetts, specializes in the development of innovative technologies for the characterization of extracellular vesicles, particularly exosomes. The company's proprietary ExoView technology uses an affinity microarray platform to enable specific binding and detection of these vesicles, facilitating high-throughput and cost-effective analysis. NanoView offers a range of products, including ExoView R100 and ExoView Tetraspanin, along with custom assays and sample services. The company's solutions aim to enhance research and the delivery of precision medicine by providing insights into the biological roles of exosomes and their potential as biomarkers for disease diagnosis, treatment, and monitoring.
General Automation Lab Technologies, Inc. discovers, develops, and commercializes gut microbe systems for microbial research and product development communities. It offers GALT Prospector, a high-throughput isolation and cultivation array system that enables scientists to access various microbes; and isolate rare/unique species to understand their functions. Its microbe systems are used in cultivation, screening, and natural product discovery applications. General Automation Lab Technologies, Inc. was founded in 2014 and is based in San Carlos, California.
Farcast is a clinical diagnostic company dedicated to providing personalized cancer treatment solutions. Its core technology utilizes a human tumor microenvironment to enable oncologists and drug developers to assess individual tumors and determine their treatment response profiles. This innovative approach aims to surpass traditional biomarker-guided strategies, thereby enhancing access to personalized medicine and improving the clinical management of cancer. Headquartered in Boston, Massachusetts, Farcast also operates a laboratory in Bangalore, India, reflecting its commitment to advancing cancer care through cutting-edge technology.
DiCE Therapeutics, founded in 2013 and based in Menlo Park, California, specializes in developing a platform for the discovery of novel small molecules aimed at targets that have previously been difficult to address in the pharmaceutical sector. The company utilizes innovative technology that extends directed evolution, allowing for the direct translation of DNA-encoded information into organic compounds, thereby streamlining the traditionally labor-intensive processes of medicinal chemistry. This platform not only serves the pharmaceutical industry but also has applications in agriculture and materials sciences. The founding team includes notable figures such as Stanford Professor Pehr Harbury, who developed the core technology, and other experienced professionals from various sectors, contributing to the company's mission of transforming drug discovery and development.
SeLux Diagnostics, Inc. is focused on advancing antibiotic susceptibility testing and infectious disease diagnostics through its innovative phenotyping platform. Founded in 2014 and located in Charlestown, Massachusetts, the company employs a unique synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing. This platform significantly improves the accuracy and timeliness of diagnosing infections, enabling healthcare providers to prescribe targeted and personalized antibiotic therapies. By facilitating informed treatment decisions, SeLux Diagnostics aims to enhance patient care, save lives, and improve overall health outcomes in hospital settings.